Investigating the impact of respiratory viruses on adults in India
Official title: RFA-IP-22-001 - Burden and sequelae of influenza, SARS-CoV-2 and other respiratory viruses associated Severe Acute Respiratory Infections among Indian adult population aged 18-60yrs
Funded at All-India Institute of Medical Sciences · NIH-10916158 · Data updated 2026-11-12
This study is looking at how influenza and COVID-19 affect working adults in India, including how often these illnesses occur, the costs of treatment, and how well vaccines work, while also understanding why some healthcare workers might be hesitant to get vaccinated, all to help improve public health in the future.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | All-India Institute of Medical Sciences NIH-funded |
| Lab location | 1 site (New Delhi, India) |
| Project start | September 30, 2023 |
| Project end | September 29, 2028 |
| Funding year | 2024 |
| Award (this year) | $750,000 |
| NIH project number | 5U01IP001171-02 |
| Project ID | NIH-10916158 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are adults aged 18-60 who have experienced severe acute respiratory infections or are healthcare workers involved in vaccination efforts.
✕Less likely to help
Patients outside the age range of 18-60 or those with mild respiratory infections may not receive direct benefits from this research.
What this research studies
This research focuses on understanding the burden and long-term effects of influenza and SARS-CoV-2 infections among working adults in India aged 18-60. It aims to estimate the incidence and treatment costs associated with severe acute respiratory infections (SARI) and to assess the effectiveness of vaccines against these viruses. The study will also explore vaccine hesitancy among healthcare workers and develop strategies for public health interventions. By establishing a national registry and network of hospitals, the research seeks to provide valuable data for evidence-based policy development.
Why it matters
Potential benefit: If successful, this research could lead to improved public health policies and better management of respiratory infections, ultimately reducing the economic burden on the adult population in India.
How similar studies have gone: Previous research has shown success in understanding the impact of respiratory viruses in various populations, making this approach both relevant and necessary.
Where this research is happening
-
All-India Institute of Medical Sciences
New Delhi, India Active
Researchers
- Principal investigator: Krishnan, Anand — All-India Institute of Medical Sciences
- Study coordinator: Krishnan, Anand
Related research
Other NIH-funded projects on the same topics.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Burden and consequences of influenza, SARS-CoV-2 and other respiratory viruses among Indian adults
This grant aims to study how flu and COVID-19 and related respiratory infections affect Indian adults 18–60, including costs, outcomes, and vaccine uptake to inform health policy.
-
Leptin and fat cells: how obesity may worsen lung infections like COVID-19 and flu
A study explores how fat tissue and the leptin pathway might change the body's first lung defenses during respiratory infections in people who are obese or have diabetes.
-
Vaccine effectiveness in preventing respiratory illness in Washington state (2022–2027)
This project tests how well vaccines against flu, COVID-19, and other respiratory viruses protect people in Washington state from getting acutely ill.
-
Understanding flu and COVID-19 vaccine responses in adults
A Stanford-led effort studies how the flu and COVID-19 vaccines work in adults and how to make them work better for people, especially those with higher risk from underlying health conditions.
-
How flu, COVID-19, and other respiratory vaccines protect people in Washington from sudden respiratory illness
This project checks how well seasonal flu, COVID-19, and other respiratory vaccines prevent short-term respiratory illnesses in people living in Washington state.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.